A citation-based method for searching scientific literature

Nitya Nathwani, Luca Bertamini, Rahul Banerjee, Francesca Gay, Nina Shah, Amrita Krishnan. Am Soc Clin Oncol Educ Book 2021
Times Cited: 2







List of co-cited articles
4 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
Philippe Moreau, Maria-Victoria Mateos, James R Berenson, Katja Weisel, Antonio Lazzaro, Kevin Song, Meletios A Dimopoulos, Mei Huang, Anita Zahlten-Kumeli, A Keith Stewart. Lancet Oncol 2018
130
100

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report.
Antonio Palumbo, Sara Bringhen, Maria-Victoria Mateos, Alessandra Larocca, Thierry Facon, Shaji K Kumar, Massimo Offidani, Philip McCarthy, Andrea Evangelista, Sagar Lonial,[...]. Blood 2015
439
100

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
Meletios A Dimopoulos, Hartmut Goldschmidt, Ruben Niesvizky, Douglas Joshua, Wee-Joo Chng, Albert Oriol, Robert Z Orlowski, Heinz Ludwig, Thierry Facon, Roman Hajek,[...]. Lancet Oncol 2017
244
100

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Michel Attal, Paul G Richardson, S Vincent Rajkumar, Jesus San-Miguel, Meral Beksac, Ivan Spicka, Xavier Leleu, Fredrik Schjesvold, Philippe Moreau, Meletios A Dimopoulos,[...]. Lancet 2019
290
100

Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010-2016).
Sundar Jagannath, Rafat Abonour, Brian G M Durie, Cristina Gasparetto, James W Hardin, Mohit Narang, Howard R Terebelo, Kathleen Toomey, Lynne Wagner, Shankar Srinivasan,[...]. Clin Lymphoma Myeloma Leuk 2018
19
50

A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.
Thomas Martin, Rachid Baz, Don M Benson, Nikoletta Lendvai, Jeffrey Wolf, Pamela Munster, Alexander M Lesokhin, Claudine Wack, Eric Charpentier, Frank Campana,[...]. Blood 2017
127
50

SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.
Jutta Deckert, Marie-Cécile Wetzel, Laura M Bartle, Anna Skaletskaya, Victor S Goldmacher, François Vallée, Qing Zhou-Liu, Paul Ferrari, Stéphanie Pouzieux, Charlotte Lahoute,[...]. Clin Cancer Res 2014
210
50

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
Meletios A Dimopoulos, Philippe Moreau, Antonio Palumbo, Douglas Joshua, Ludek Pour, Roman Hájek, Thierry Facon, Heinz Ludwig, Albert Oriol, Hartmut Goldschmidt,[...]. Lancet Oncol 2016
580
50

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma.
Nina Shah, Jack Aiello, David E Avigan, Jesus G Berdeja, Ivan M Borrello, Ajai Chari, Adam D Cohen, Karthik Ganapathi, Lissa Gray, Damian Green,[...]. J Immunother Cancer 2020
16
50

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
Philippe Moreau, Meletios-Athanasios Dimopoulos, Joseph Mikhael, Kwee Yong, Marcelo Capra, Thierry Facon, Roman Hajek, Ivan Špička, Ross Baker, Kihyun Kim,[...]. Lancet 2021
66
50

Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.
Inger S Nijhof, Richard W J Groen, Willy A Noort, Berris van Kessel, Regina de Jong-Korlaar, Joost Bakker, Jeroen J L van Bueren, Paul W H I Parren, Henk M Lokhorst, Niels W C J van de Donk,[...]. Clin Cancer Res 2015
111
50

B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.
Nina Shah, Ajai Chari, Emma Scott, Khalid Mezzi, Saad Z Usmani. Leukemia 2020
139
50

Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials.
Ajai Chari, A Keith Stewart, Stuart D Russell, Philippe Moreau, Joerg Herrmann, Jose Banchs, Roman Hajek, John Groarke, Alexander R Lyon, George N Batty,[...]. Blood Adv 2018
40
50

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
Antonio Palumbo, Asher Chanan-Khan, Katja Weisel, Ajay K Nooka, Tamas Masszi, Meral Beksac, Ivan Spicka, Vania Hungria, Markus Munder, Maria V Mateos,[...]. N Engl J Med 2016
940
50

Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma.
Meletios Dimopoulos, Sara Bringhen, Pekka Anttila, Marcelo Capra, Michele Cavo, Craig Cole, Cristina Gasparetto, Vania Hungria, Matthew Jenner, Vladimir Vorobyev,[...]. Blood 2021
21
50

Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma.
Thomas Martin, Stephen Strickland, Martha Glenn, Eric Charpentier, Hélène Guillemin, Karl Hsu, Joseph Mikhael. Blood Cancer J 2019
63
50

Chromosome 1q21 abnormalities in multiple myeloma.
Timothy M Schmidt, Rafael Fonseca, Saad Z Usmani. Blood Cancer J 2021
27
50

SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide.
H Jiang, C Acharya, G An, M Zhong, X Feng, L Wang, N Dasilva, Z Song, G Yang, F Adrian,[...]. Leukemia 2016
147
50

Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2021.
Ivo Demel, Julio Rodriguez Bago, Roman Hajek, Tomas Jelinek. Br J Haematol 2021
13
50

The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma.
Laura Moreno, Cristina Perez, Aintzane Zabaleta, Irene Manrique, Diego Alignani, Daniel Ajona, Laura Blanco, Marta Lasa, Patricia Maiso, Idoia Rodriguez,[...]. Clin Cancer Res 2019
117
50

Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.
Thomas G Martin, Kathryn Corzo, Marielle Chiron, Helgi van de Velde, Giovanni Abbadessa, Frank Campana, Malini Solanki, Robin Meng, Helen Lee, Dmitri Wiederschain,[...]. Cells 2019
69
50

Evolution of multiple myeloma treatment practices in Europe from 2014 to 2016.
Marc S Raab, Leah Fink, Paul Schoen, Sebastian Gonzalez-McQuire, Alain Flinois, Michele Cavo, Maria-Victoria Mateos, Kwee Yong. Br J Haematol 2019
14
50

Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study.
Nizar J Bahlis, Meletios A Dimopoulos, Darrell J White, Lotfi Benboubker, Gordon Cook, Merav Leiba, P Joy Ho, Kihyun Kim, Naoki Takezako, Philippe Moreau,[...]. Leukemia 2020
98
50

Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups.
Robert Z Orlowski, Philippe Moreau, Ruben Niesvizky, Heinz Ludwig, Albert Oriol, Wee Joo Chng, Hartmut Goldschmidt, Zhao Yang, Amy S Kimball, Meletios Dimopoulos. Clin Lymphoma Myeloma Leuk 2019
33
50

Drug-Disease Interaction and Time-Dependent Population Pharmacokinetics of Isatuximab in Relapsed/Refractory Multiple Myeloma Patients.
Jean-Baptiste Fau, Raouf El-Cheikh, Claire Brillac, Kimiko Koiwai, Nathalie Mace, Frank Campana, Dorothee Semiond, Laurent Nguyen. CPT Pharmacometrics Syst Pharmacol 2020
10
50


The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies.
M S van der Veer, M de Weers, B van Kessel, J M Bakker, S Wittebol, P W H I Parren, H M Lokhorst, T Mutis. Blood Cancer J 2011
80
50

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Meletios A Dimopoulos, Albert Oriol, Hareth Nahi, Jesus San-Miguel, Nizar J Bahlis, Saad Z Usmani, Neil Rabin, Robert Z Orlowski, Mieczyslaw Komarnicki, Kenshi Suzuki,[...]. N Engl J Med 2016
936
50

Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR.
Maria-Victoria Mateos, Pieter Sonneveld, Vania Hungria, Ajay K Nooka, Jane A Estell, Wolney Barreto, Paolo Corradini, Chang-Ki Min, Eva Medvedova, Katja Weisel,[...]. Clin Lymphoma Myeloma Leuk 2020
40
50

A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab.
Joseph Mikhael, Karim Belhadj-Merzoug, Cyrille Hulin, Laure Vincent, Philippe Moreau, Cristina Gasparetto, Ludek Pour, Ivan Spicka, Ravi Vij, Jeffrey Zonder,[...]. Blood Cancer J 2021
26
50

Trends in the multiple myeloma treatment landscape and survival: a U.S. analysis using 2011-2019 oncology clinic electronic health record data.
Megan Braunlin, Rajesh Belani, Jacqueline Buchanan, Travis Wheeling, Christopher Kim. Leuk Lymphoma 2021
10
50

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.
Meletios Dimopoulos, Hang Quach, Maria-Victoria Mateos, Ola Landgren, Xavier Leleu, David Siegel, Katja Weisel, Hui Yang, Zandra Klippel, Anita Zahlten-Kumeli,[...]. Lancet 2020
175
50

Emerging immunotherapies in multiple myeloma.
Urvi A Shah, Sham Mailankody. BMJ 2020
37
50

Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR.
Hervé Avet-Loiseau, Jesus San-Miguel, Tineke Casneuf, Shinsuke Iida, Sagar Lonial, Saad Z Usmani, Andrew Spencer, Philippe Moreau, Torben Plesner, Katja Weisel,[...]. J Clin Oncol 2021
31
50

Immune signatures associated with improved progression-free and overall survival for myeloma patients treated with AHSCT.
Christine M Ho, Philip L McCarthy, Paul K Wallace, Yali Zhang, Ahmad Fora, Patrick Mellors, Joseph D Tario, Benjamin L S McCarthy, George L Chen, Sarah A Holstein,[...]. Blood Adv 2017
32
50

Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma.
Thomas G Martin, Nina Shah, Joshua Richter, David H Vesole, Sandy W Wong, Chiung-Yu Huang, Deepu Madduri, Sundar Jagannath, David S Siegel, Noa Biran,[...]. Cancer 2021
6
50

IMWG consensus on risk stratification in multiple myeloma.
W J Chng, A Dispenzieri, C-S Chim, R Fonseca, H Goldschmidt, S Lentzsch, N Munshi, A Palumbo, J S Miguel, P Sonneveld,[...]. Leukemia 2014
384
50

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.
Shaji Kumar, Bruno Paiva, Kenneth C Anderson, Brian Durie, Ola Landgren, Philippe Moreau, Nikhil Munshi, Sagar Lonial, Joan Bladé, Maria-Victoria Mateos,[...]. Lancet Oncol 2016
50

Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells.
Chen Zhu, Zhili Song, Anlai Wang, Srimathi Srinivasan, Guang Yang, Rita Greco, Joachim Theilhaber, Elvis Shehu, Lan Wu, Zhi-Yong Yang,[...]. Front Immunol 2020
37
50

Systolic dysfunction associated with carfilzomib use in patients with multiple myeloma.
Tania Jain, Hemalatha Narayanasamy, Joseph Mikhael, Craig B Reeder, P Leif Bergsagel, Angela Mayo, A Keith Stewart, Farouk Mookadam, Rafael Fonseca. Blood Cancer J 2017
11
50

A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma.
Joseph Mikhael, Joshua Richter, Ravi Vij, Craig Cole, Jeffrey Zonder, Jonathan L Kaufman, William Bensinger, Meletios Dimopoulos, Nikoletta Lendvai, Parameswaran Hari,[...]. Leukemia 2020
22
50

Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma.
Xiaoyan Feng, Li Zhang, Chirag Acharya, Gang An, Kenneth Wen, Lugui Qiu, Nikhil C Munshi, Yu-Tzu Tai, Kenneth C Anderson. Clin Cancer Res 2017
147
50

The Multi-faceted Ecto-enzyme CD38: Roles in Immunomodulation, Cancer, Aging, and Metabolic Diseases.
Kelly A Hogan, Claudia C S Chini, Eduardo N Chini. Front Immunol 2019
130
50

Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions.
Chiara Caraccio, Sachi Krishna, Darci J Phillips, Christian M Schürch. Front Immunol 2020
54
50

Individualized genetic makeup that controls natural killer cell function influences the efficacy of isatuximab immunotherapy in patients with multiple myeloma.
Haibo Sun, Thomas G Martin, John Marra, Denice Kong, Jonathon Keats, Sandrine Macé, Marielle Chiron, Jeffrey L Wolf, Jeffrey M Venstrom, Raja Rajalingam. J Immunother Cancer 2021
5
50

Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design.
Philippe Moreau, Meletios A Dimopoulos, Kwee Yong, Joseph Mikhael, Marie-Laure Risse, Gaëlle Asset, Thomas Martin. Future Oncol 2020
40
50

A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.
Joseph Mikhael, Paul Richardson, Saad Z Usmani, Noopur Raje, William Bensinger, Chatchada Karanes, Frank Campana, Dheepak Kanagavel, Franck Dubin, Qianying Liu,[...]. Blood 2019
63
50

Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma.
Pashna N Munshi, David Vesole, Artur Jurczyszyn, Jan Maciej Zaucha, Andrew St Martin, Omar Davila, Vaibhav Agrawal, Sherif M Badawy, Minoo Battiwalla, Saurabh Chhabra,[...]. Cancer 2020
23
50

The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial.
Charlotte Pawlyn, David Cairns, Martin Kaiser, Alina Striha, John Jones, Vallari Shah, Matthew Jenner, Mark Drayson, Roger Owen, Walter Gregory,[...]. Leukemia 2020
38
50

Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life.
Evangelos Terpos, Joseph Mikhael, Roman Hajek, Ajai Chari, Sonja Zweegman, Hans C Lee, María-Victoria Mateos, Alessandra Larocca, Karthik Ramasamy, Martin Kaiser,[...]. Blood Cancer J 2021
21
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.